News

‘Revolutionary Eye and Vision Research’ theme of annual meeting.

Santen, Massachusetts Eye and Ear, Ulster University researchers will focus on ways to preserve vision by slowing, reversing, or preventing the damage.

Ocuphire Pharma’s ZETA-1 trial will investigate the potential of APX3330 to offer an oral treatment for diabetic retinopathy.

A diminishment of both hearing and vision is linked to an increased risk for dementia and mental decline, according to a new study.

Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery.

According to Verizon Business, BlueJeans Telehealth is way for providers and patients to conduct data-driven virtual care conversations.

During the trial, a patient gained vision, which lasted more than a year, after a single injection of an experimental RNA therapy into the eye.

The American Academy of Ophthalmology’s Truhlsen-Marmor Museum of the Eye is offering a free 2-part virtual series that will provide attendees an idea what is going on inside of their very own eyes and gut.

Drinking alcohol on a regular basis may decrease patients’ chances of developing cataracts that require surgery, new research shows.

A decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent committee.

Clinical-stage pharma company announces next step in investigation of BRIMOCHOL to treat presbyopia.

ProQR Therapeutics has unveiled the results from its Phase 1/2 Stellar trial examining QR-421a n patients with Usher syndrome and non-syndromic retinitis pigmentosa.

A clinical trial of NCX 470 will evaluate the drug for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

SemaThera Inc. has announced a research collaboration and licensing agreement with Roche to develop a new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.

A group of French researchers is hoping its work to develop an artificial retina will help blind people see again.

Phase 2 trial of 0.3% minocycline microparticle suspension shows promise in dry eye diseases associated with Inflamed meibomian gland dysfunction

RegeneRx Biopharmaceuticals announces that its ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops did not meet its primary outcome measures.

According to a national study, serious vision issues among older Americans have dropped sharply, with the greatest improvement found among women, individuals over 85 and Black or Hispanic seniors.

Researchers at the Royal College of Ophthalmologists offer guidance on the impact of treatment delays in crosslinking (CXL) amid COVID-19 on patients with keratoconus.

Visus Therapeutics announced today that FDA has approved its Investigational New Drug Application (IND) to move forward with the clinical development program for BRIMOCHOL

Graybug Vision, Inc. has reported preliminary topline data from a 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

A Canadian artificial cornea clinical trial has been enhanced by a remote, real-time 3D HD video training solution.

The study will evaluate the safety and tolerability of the R:GEN laser in patients with early-stage age-related macular degeneration.

Citing an unstable supply chain, Pfizer is discontinuing the ophthalic drops.

George Marcellino, vice president of Iridex, is being remembered by colleagues as a man of substance.

Topcon Corp. will purchase exclusive rights to distribute Iridex Corp.’s retina and glaucoma products, while also acquiring a common equity stake in the company. Iridex will acquire Topcon’s PASCAL product line.

The FDA has accepted Oyster Point Pharma's New Drug Application (NDA) for its OC-01 (varenicline) nasal spray to treat dry eye disease.

Visits, elective procedures decreased as physicians responded to COVID-19 guidelines.